Dark

CTLT
CATALENT, INC.
stock NYSE

Inactive

Dec 17, 2024

63.48USD0.000%(0.00)13,669,337

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-63.48)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

10:39AM EST Earnings Outlook For Catalent Benzinga

Jan 27, 2022

11:03AM EST Expert Ratings For Catalent Benzinga

06:46AM EST Barclays Maintains Overweight on Catalent, Lowers Price Target to $130 Benzinga

Jan 21, 2022

08:15AM EST Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast Business Wire

Jan 14, 2022

08:48AM EST FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report Benzinga

Jan 5, 2022

08:22AM EST Catalent : Alessandro Maselli To Become New CEO Effective July 1, 2022 RTTNews

08:00AM EST Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022 Business Wire

Jan 3, 2022

04:15PM EST Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 30, 2021

09:50AM EST A Look Into Catalent's Price Over Earnings Benzinga

Dec 17, 2021

11:02AM EST Edenbridge Pharma Reports Catalent-Manufactured Drug DARTISLA ODT Orally Disintegrating Tablet Approved By FDA Benzinga

Dec 16, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 Benzinga

06:55AM EST Barclays Initiates Coverage On Catalent with Overweight Rating, Announces Price Target of $160 Benzinga

Dec 7, 2021

07:09AM EST BrainStorm Cell Therapeutics And Catalent Announce Completion Of Technology Transfer For NurOwn Manufacturing Benzinga

Nov 23, 2021

05:15PM EST Catalent, Inc. to Present at the Stephens Annual Investment Conference Business Wire

Nov 3, 2021

12:41PM EDT Expert Ratings For Catalent Benzinga

10:04AM EDT Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $160 Benzinga

09:20AM EDT RBC Capital Maintains Outperform on Catalent, Raises Price Target to $155 Benzinga

Nov 2, 2021

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:50AM EDT Catalent Raises FY22 Guidance: Net Sales From $4.3B-$4.5B To $4.62B-$4.82B vs $4.5B Estimate, Adj. EBITDA From $1.13B-$1.2B To $1.225B-$1.295B Benzinga

10:50AM EDT Catalent Q1 Adj. EPS $0.71 Beats $0.65 Estimate, Sales $1.02B Miss $1.03B Estimate Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

07:09AM EDT Catalent Q1 Net Earnings $93 Mln Vs $82 Mln Last Year RTTNews

07:00AM EDT Catalent, Inc. Reports First Quarter Fiscal 2022 Results Business Wire

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 20, 2021

05:15PM EDT Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast Business Wire

Sep 23, 2021

06:49PM EDT Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030 Business Wire

07:53AM EDT Catalent Announces Launch Of Private Offering Of $450 Mln Of Senior Unsecured Notes Due 2030 RTTNews

07:49AM EDT Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030 Business Wire

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 9, 2021

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

Sep 8, 2021

12:37PM EDT Where Catalent Stands With Analysts Benzinga

08:40AM EDT Deutsche Bank Maintains Hold on Catalent, Raises Price Target to $162 Benzinga

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

Sep 7, 2021

07:45AM EDT Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Business Wire

Sep 3, 2021

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Aug 31, 2021

10:10AM EDT UBS Maintains Buy on Catalent, Raises Price Target to $145 Benzinga

07:59AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:28AM EDT Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $147 Benzinga

07:13AM EDT RBC Capital Maintains Outperform on Catalent, Raises Price Target to $145 Benzinga

06:38AM EDT B of A Securities Maintains Buy on Catalent, Raises Price Target to $160 Benzinga

04:31AM EDT Keybanc Maintains Overweight on Catalent, Raises Price Target to $155 Benzinga

Aug 30, 2021

02:35PM EDT Mid-Afternoon Market Update: Affirm Shares Jump Following News Of Amazon Partnership; Adtran Shares Drop Benzinga

12:29PM EDT Mid-Day Market Update: Nasdaq Jumps Over 100 Points; Astra Space Shares Plunge Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Mixed; Catalent To Acquire Bettera Benzinga

08:44AM EDT Catalent Makes Strategic Move For Consumer Health Business With Bettera Deal Benzinga

07:28AM EDT Catalent, Inc. (CTLT) reported an increase in profit for the fourth quarter that also topped Wall Street estimates. Overall organic net revenue growth was 26%, for the quarter. The company also announced an agreement to acquire Bettera Holdings. RTTNews

07:12AM EDT CORRECTION: Catalent Q4 Sales $1.19B Benzinga

07:11AM EDT Catalent Q4 EPS $1.16 Beats $1.03 Estimate, Sales $1.19B Beat $1.14B Estimate Benzinga

07:10AM EDT Catalen To Buy Highlander's Portfolio Company, Bettera Holdings For $1 Bln RTTNews

07:05AM EDT Catalent Q4 Adj. EPS $1.16, Consensus $1.03 RTTNews

07:04AM EDT Catalent To Buy Highlander's Portfolio Co. Bettera Holdings, LLC, For $1 Bln RTTNews

07:04AM EDT Catalent to Acquire Bettera, a Gummy Manufacturer, for $1B Benzinga

07:03AM EDT Catalent Sees FY22 Sales $4.30B-$4.50B vs $3.94B Est. Benzinga

07:02AM EDT Catalent Q4 Adj. EPS $1.16 Beats $1.03 Estimate, Sales $1.19M Miss $1.14B Estimate Benzinga

07:01AM EDT Highlander Partners Announces the Signing of a Definitive Agreement to Sell PR Newswire

07:00AM EDT Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent Business Wire

07:00AM EDT Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results Business Wire

07:00AM EDT Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer Business Wire

06:23AM EDT A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs Benzinga

04:05AM EDT Earnings Scheduled For August 30, 2021 Benzinga

Aug 29, 2021

11:34PM EDT Contract drug manufacturer Catalent Inc. (CTLT) has agreed to acquire closely held vitamin and supplements maker Bettera Holdings for $1 billion in cash, the Wall Street Journal reported citing people familiar with the matter. RTTNews

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 26, 2021

08:09AM EDT The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO Benzinga

Aug 25, 2021

09:49AM EDT A Look Into Catalent's Price Over Earnings Benzinga

06:33AM EDT Catalent's Debt Overview Benzinga

05:41AM EDT EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines Benzinga

Aug 10, 2021

10:23AM EDT Catalent Will Supply Edenbridge Pharma With Patient-Focused Fast-Dissolve Zydis Formulation Of Glycopyrrolate Benzinga

Aug 6, 2021

09:00AM EDT Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast Business Wire

Aug 3, 2021

09:00AM EDT Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint Business Wire

Jul 29, 2021

10:11AM EDT 2 Stocks Insiders Are Buying Benzinga

Jul 21, 2021

02:14PM EDT Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant Benzinga

04:58AM EDT Catalent Announced Plans for Multi-Phase, $100M Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe Benzinga

Jun 4, 2021

09:00AM EDT Catalent, Inc. to Present at the Biopharma CEO Investor Forum Business Wire

Jun 3, 2021

08:33AM EDT AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT Benzinga

May 28, 2021

08:48AM EDT Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference Business Wire

May 21, 2021

08:45AM EDT Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference Business Wire

May 13, 2021

08:59AM EDT Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry Business Wire

May 11, 2021

07:23AM EDT Catalent Announces Chief Financial Officer Succession Benzinga

07:06AM EDT Catalent Promotes Thomas Castellano To SVP And CFO, Effective June 1, Succeeding Wetteny Joseph RTTNews

07:00AM EDT Catalent Announces Chief Financial Officer Succession Business Wire

May 10, 2021

04:44PM EDT FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic Benzinga

May 7, 2021

09:00AM EDT Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference Business Wire

May 6, 2021

03:13PM EDT Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

07:43AM EDT Catalent: Q3 Earnings Insights Benzinga

07:29AM EDT Catalent, Inc. Q3 Net Earnings $231.8 Mln Vs. $20.9 Mln Last Year RTTNews

07:04AM EDT UPDATE: Catalent Narrows, Raises Low End Of FY21 Net Sales Growth Guidance From 23-28% Year Over Year To 25-28%, Adj. EBITDA Growth From 26-33% To 30-35% Benzinga

07:03AM EDT Catalent Q3 Adj. EPS $0.82 Beats $0.74 Estimate, Sales $1.05B Beat $993.20M Estimate; Raises Guidance Benzinga

06:59AM EDT Catalent, Inc. Reports Third Quarter Fiscal 2021 Results Business Wire

Apr 29, 2021

08:26AM EDT Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually Benzinga

Apr 19, 2021

08:30AM EDT Catalent, Inc. Announces Third Quarter Fiscal Year 2021 Earnings Conference Webcast Business Wire

Apr 6, 2021

09:20AM EDT Moderna Inc. (MRNA) and Catalent Inc. (CTLT) said that they have expanded their strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 vaccine and potentially other investigational programs in Moderna's pipeline, at Catalent's biologics facility in Bloomington, Indiana. RTTNews

09:04AM EDT Moderna, Catalent Announce Long-Term Collaboration For Vial Filling Of Moderna's COVID-19 Vaccine And Clinical Portfolio RTTNews

09:04AM EDT Moderna, Catalent Announce Expansion Of Strategic Collaboration RTTNews

09:01AM EDT Moderna And Catalent Announce Collaboration To 'dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs in Moderna's pipeline'; Financial Details Not Disclosed Benzinga

09:00AM EDT Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna's COVID-19 Vaccine and Clinical Portfolio Business Wire

07:33AM EDT Catalent To Boost Output Of Finished Vials For Moderna's COVID-19 Shot: WSJ Benzinga

Mar 24, 2021

06:06AM EDT A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Data, Fed Speakers Benzinga

02:14AM EDT J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Secures Key FDA Clearance Benzinga

02:13AM EDT J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Catalent Secures Key FDA Clearance Benzinga

Mar 23, 2021

01:44PM EDT Catalent Is Said To Receive FDA Approval To Make Johnson & Johnson Vaccine, Expected To Release Millions Of Doses Upon Clearance Benzinga

Mar 22, 2021

07:20AM EDT Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine Benzinga

07:15AM EDT Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003) Business Wire

Mar 18, 2021

08:41AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Mar. 18, 2021: CTLT, LIZI, YVR, MFH, HOFV Benzinga

Mar 17, 2021

09:14AM EDT UPDATE: Catalent Says Will Accelerate Qualification, Scale-Up Of Added High-Speed Vial-Filling Line, Expected To Be Operational In Q4'21, Expanded Deal Will Support Production Of J&J's Janssen Vaccine Through Late 2022 Benzinga

09:13AM EDT Catalent Expands Existing Partnership With J&J To Increase Capacity For Sterile Manufacturing, Packaging Of COVID-19 Vaccine In Italy Benzinga

Mar 2, 2021

08:32AM EST JNJ Accelerated COVID-19 Vaccine Shipment Dependent On New Plant Approval Benzinga

Feb 24, 2021

10:42AM EST Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes Benzinga

Feb 23, 2021

07:43AM EST Catalent to Acquire Delphi Genetics And Launch US Plasmid Manufacturing Site; Financial Terms Not Disclosed Benzinga

Feb 19, 2021

04:15PM EST Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference Business Wire

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 16, 2021

05:07PM EST 13F From Dan Loeb's Third Point Shows New Stakes In Zillow, Vontier, Upstart Holdings, UnitedHealth, Stanley Black & Decker, RH, Estee Lauder, Intel, Fortive, ContextLogic, Catalent, Bright Horizons, Aptiv, Altimeter Benzinga

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 10, 2021

04:49PM EST Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029 Business Wire

07:44AM EST Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029 Business Wire

Feb 3, 2021

09:02AM EST Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $135 Benzinga

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Feb 2, 2021

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

07:49AM EST Catalent Q2 EPS $0.46 Vs $0.23 Last Year RTTNews

07:37AM EST Catalent: Q2 Earnings Insights Benzinga

07:16AM EST UPDATE: Catalent Raises FY21 Net Sales Guidance From $3.58B-$3.78B To $3.8B-$3.95B vs $3.73B Estimate, Adj. EBITDA From $880M-$950M To $950M-$1B Benzinga

07:16AM EST Catalent Raises Guidance Benzinga

07:15AM EST Catalent Q2 Adj. EPS $0.63 Beats $0.55 Estimate, Sales $910.80M Beat $894.58M Estimate Benzinga

07:15AM EST Catalent, Inc. Reports Second Quarter Fiscal 2021 Results Business Wire

04:00AM EST Earnings Scheduled For February 2, 2021 Benzinga

Feb 1, 2021

10:07AM EST Earnings Preview: Catalent Benzinga

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 20, 2021

08:45AM EST Catalent, Inc. Announces Second Quarter Fiscal Year 2021 Earnings Conference Webcast Business Wire

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

07:09AM EST Acorda Therapeutics Announces Agreement To Sell Its INBRIJA Manufacturing Operations In Chelsea, Massachusetts To Catalent For $80M In Cash Benzinga

07:06AM EST UPDATE: In Connectoin With Sale, Acorda And Catalent Have Entered Into A Long-term Global Supply Agreement Under Which Catalent Will Manufacture And Package INBRIJA For Acorda Benzinga

Jan 6, 2021

08:55AM EST Catalent, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 21, 2020

09:03AM EST Novan Enters Into Master Services Agreement With Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program Benzinga

Dec 10, 2020

10:30AM EST KeyBanc Upgrades Catalent On Industry Transformation Benzinga

06:11AM EST A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Earnings, Economic Data Benzinga

04:40AM EST KeyBanc Upgrades Catalent to Overweight, Announces $120 Price Target Benzinga

Dec 7, 2020

07:14AM EST Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products Benzinga

Nov 13, 2020

01:01PM EST Final Trades On CNBC: Jon Najarian Buys Host, Shannon Saccocio Buys EA, Jason Snipe Buys Catalent, Stephanie Link Buys John Deere, Liz Young Buys SPDR Retail ETF, Benzinga

Nov 11, 2020

09:16AM EST Catalent, Inc. to Present at November 2020 Virtual Investor Conferences Business Wire

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

Nov 5, 2020

07:27AM EST Taysha Gene Therapies Announces Co Bolstering Manufacturing Capacity Through Partnership With Catalent Benzinga

Nov 4, 2020

08:06AM EST Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $115 Benzinga

Nov 3, 2020

09:52AM EST A Look Into Catalent's Price Over Earnings Benzinga

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

07:29AM EST Catalent Q1 Earnings Attributable To Common Shareholders $68.8 Mln Or $0.42/Shr Vs Loss $8.0 Mln Or $0.05/Shr Last Year RTTNews

07:20AM EST Catalent Raises FY21 Sales Guidance From $3.45B-$3.60B To $3.58B-$3.78B vs $3.57B Est. Benzinga

07:18AM EST Catalent Q1 Adj. EPS $0.43 Beats $0.37 Estimate, Sales $845.70M Beat $811.37M Estimate Benzinga

07:15AM EST Catalent, Inc. Reports First Quarter Fiscal 2021 Results Business Wire

04:07AM EST Earnings Scheduled For November 3, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

09:10AM EDT Catalent, BrainStorm Cell Therapeutics Report Partnership To Manufacture Mesenchymal Stem Cell Platform, NurOwn, No Terms Disclosed Benzinga

09:01AM EDT Catalent and BrainStorm Cell Therapeutics Announce Partnership for GlobeNewswire Inc

Oct 16, 2020

09:00AM EDT Catalent, Inc. Announces First Quarter Fiscal Year 2021 Earnings Conference Webcast Business Wire

Sep 21, 2020

05:35AM EDT T-knife, Catalent To Provide Technology Transfer, CGMP Clinical Manufacturing Of T1367 TCR Program RTTNews

Sep 8, 2020

08:59AM EDT A Look Into Catalent's Debt Benzinga

Sep 4, 2020

08:09PM EDT Tesla Shares Fall After Stock Was Not Added To The S&P 500 Benzinga

06:03PM EDT Etsy, Teradyne and Catalent Set to Join S&P 500; Others to Join S&P MidCap 400 PR Newswire

Sep 3, 2020

08:00AM EDT Catalent, Inc. to Present at September 2020 Virtual Investor Conferences Business Wire

Sep 1, 2020

07:39AM EDT Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $98 Benzinga

Aug 31, 2020

11:19AM EDT Why Catalent's Stock Is Trading Higher Today Benzinga

10:10AM EDT Shares of Catalent Inc. (CTLT), which have been trading in the range of $31.04 - $91.95 for the past one year, are trading closer to its 52-week high of $91.95. CTLT is currently trading at $90.51, up $2.85 or 3.26% in regular trading session. RTTNews

09:24AM EDT CORRECTION: Catalent Sees FY21 Sales $3.45B-$3.60B vs $3.05B Estimate Benzinga

09:24AM EDT Catalent Sees FY21 Sales $3.45B-$3.60B vs $3.05B Estimate Benzinga

07:47AM EDT Catalent: Q4 Earnings Insights Benzinga

07:17AM EDT Catalent Sees FY21 Sales $3.45B-$3.60B vs $2.16 Est. Benzinga

07:15AM EDT Catalent, Inc. Reports Fourth Quarter Fiscal 2020 Results Business Wire

07:15AM EDT Catalent Q4 Adj. EPS $0.90 Beats $0.79 Estimate, Sales $947.60M Beat $895.51M Estimate Benzinga

06:06AM EDT A Peek Into The Markets: US Stock Futures Gain Ahead Of Zoom Earnings Benzinga

04:01AM EDT Earnings Scheduled For August 31, 2020 Benzinga

Aug 30, 2020

08:24AM EDT The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing Benzinga

Aug 24, 2020

10:18AM EDT A Look Into Catalent's Price Over Earnings Benzinga

08:27AM EDT Catalent's Maryland Facility To Provide Manufacturing RTTNews

08:12AM EDT Catalent Signs Deal With AstraZeneca To Expand Manufacturing Support For COVID-19 Vaccine AZD1222 RTTNews

08:08AM EDT Catalent to Produce AstraZeneca's COVID-19 Vaccine Candidate Benzinga

08:00AM EDT Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222 Business Wire

Jul 31, 2020

08:06AM EDT Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $95 Benzinga

Jul 30, 2020

08:20AM EDT Catalent Now Expects FY20 Net Revenue Of $3.084 Bln - $3.096 Bln RTTNews

08:15AM EDT Catalent Sees Q4 Adj. EBITDA $262M-$266M, Sales $937M-$949M vs $776.7M Estimate; FY20 Adj. EBITDA $745M-$749M, Sales $3.084B-$3.096B vs $2.92B Est. Benzinga

08:13AM EDT Catalent, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2020 Net Revenue, Earnings Before Income Taxes, and Adjusted EBITDA Significantly Ahead of Its Previous Guidance Business Wire

Jul 29, 2020

08:07AM EDT Catalent Enters Into Strategic Partnership With Editas Medicine To Support Gene Editing Medicine Pipeline Benzinga

Jul 27, 2020

09:17PM EDT Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development Benzinga

Jul 16, 2020

07:37AM EDT Catalent Biologics and Humanigen, Inc. (HGEN) announced Thursday the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen's proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. RTTNews

document.getElementById("ZC6zhG").onerror = function(){this.style.display='none';}; .dark-mode .WVXlgZ{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .WVXlgZ{ color: #333333; background-color: white; border: 2px solid #333333; }CTLTCATALENT, INC.stock NYSE

CTLT
CATALENT, INC.
stock NYSE